Insider · CIK 0001353528

Cassella James V

Reports to the SEC for 3 companies · NEW HAVEN, CT

sec.gov

Transactions

Companies

Filings

CIK

0001353528

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-19	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+215K sh	—	—	215,000
2025-02-18	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+258K sh	—	—	257,500
2024-09-30	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+400K sh	—	—	400,000
2024-06-13	TRVITrevi Therapeutics, Inc. · Nonstatutory Stock Option (right to buy)A Award	Chief Development Officer	AAward	+30K sh	—	—	30,000
2023-06-28	TRVITrevi Therapeutics, Inc. · Nonstatutory Stock Option (right to buy)A Award	Chief Development Officer	AAward	+30K sh	—	—	30,000
2023-03-06	CONCERT PHARMACEUTICALS, INC.U Disposition from Tender	Chief Development Officer	UDisposition from Tender	−80.6K sh	—	—	0
2023-03-06	CONCERT PHARMACEUTICALS, INC.D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−57.8K sh	—	—	0
2023-03-06	CONCERT PHARMACEUTICALS, INC.Performance Stock UnitsD Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−34.7K sh	—	—	0
2023-03-06	CONCERT PHARMACEUTICALS, INC.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−140K sh	—	—	0
2023-03-06	CONCERT PHARMACEUTICALS, INC.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−50K sh	—	—	0
2023-03-06	CONCERT PHARMACEUTICALS, INC.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−70K sh	—	—	0
2023-03-06	CONCERT PHARMACEUTICALS, INC.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−49.5K sh	—	—	0
2023-03-06	CONCERT PHARMACEUTICALS, INC.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−75K sh	—	—	0
2023-03-06	CONCERT PHARMACEUTICALS, INC.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−42.4K sh	—	—	0
2023-03-06	CONCERT PHARMACEUTICALS, INC.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−60.4K sh	—	—	0
2023-02-15	CONCERT PHARMACEUTICALS, INC.S Sale	Chief Development Officer	SSale	−3,762 sh	$8.34	−$31.4K	173,061
2023-01-30	CONCERT PHARMACEUTICALS, INC.S Sale	Chief Development Officer	SSale	−10.1K sh	$8.35	−$84.4K	176,823
2023-01-06	CONCERT PHARMACEUTICALS, INC.S Sale	Chief Development Officer	SSale	−2,893 sh	$7.25	−$21K	186,929
2022-06-23	TRVITrevi Therapeutics, Inc. · Nonstatutory Stock Option (right to buy)A Award	Chief Development Officer	AAward	+20K sh	—	—	20,000
2022-06-23	TRVITrevi Therapeutics, Inc. · Nonstatutory Stock Option (right to buy)A Award	Chief Development Officer	AAward	+20K sh	—	—	20,000
2022-02-14	CONCERT PHARMACEUTICALS, INC.S Sale	Chief Development Officer	SSale	−3,762 sh	$3.09	−$11.6K	189,822
2022-01-28	CONCERT PHARMACEUTICALS, INC.A Award	Chief Development Officer	AAward	+75.8K sh	—	—	158,884
2022-01-28	CONCERT PHARMACEUTICALS, INC.A Award	Chief Development Officer	AAward	+34.7K sh	—	—	193,584
2022-01-05	CONCERT PHARMACEUTICALS, INC.S Sale	Chief Development Officer	SSale	−2,894 sh	$3.19	−$9,231.86	83,084
2021-08-16	CONCERT PHARMACEUTICALS, INC.S Sale	Chief Development Officer	SSale	−8,086 sh	$3.28	−$26.5K	85,978
2021-06-16	TRVITrevi Therapeutics, Inc. · Nonstatutory Stock Option (right to buy)A Award	Chief Development Officer	AAward	+20K sh	—	—	20,000
2021-02-16	CONCERT PHARMACEUTICALS, INC.S Sale	Chief Development Officer	SSale	−3,763 sh	$7.32	−$27.5K	94,064
2021-01-05	CONCERT PHARMACEUTICALS, INC.A Award	Chief Development Officer	AAward	+21.7K sh	—	—	97,827
2021-01-05	CONCERT PHARMACEUTICALS, INC.Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+60.4K sh	—	—	60,400
2020-08-17	CONCERT PHARMACEUTICALS, INC.S Sale	Chief Development Officer	SSale	−4,354 sh	$10.37	−$45.2K	76,127
2020-02-14	CONCERT PHARMACEUTICALS, INC.A Award	Chief Development Officer	AAward	+28.2K sh	—	—	80,481
2020-02-14	CONCERT PHARMACEUTICALS, INC.Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+42.4K sh	—	—	42,430
2020-02-13	TRVITrevi Therapeutics, Inc. · Nonstatutory Stock Option (right to buy)A Award	Chief Development Officer	AAward	+23.7K sh	—	—	23,684
2019-08-15	CONCERT PHARMACEUTICALS, INC.A Award	Chief Development Officer	AAward	+31.1K sh	—	—	52,265
2019-03-31	CONCERT PHARMACEUTICALS, INC.F Tax Payment	Chief Development Officer	FTax Payment	−8,835 sh	$12.07	−$107K	21,165
2019-01-04	CONCERT PHARMACEUTICALS, INC.Employee Stock Option (right to buy)A Award	Chief Development Officer	AAward	+75K sh	—	—	75,000
2018-04-17	CONCERT PHARMACEUTICALS, INC.S Sale	Chief Development Officer	SSale	−10.6K sh	$20.18	−$214K	30,000
2018-03-31	CONCERT PHARMACEUTICALS, INC.F Tax Payment	Chief Development Officer	FTax Payment	−4,418 sh	$22.90	−$101K	40,582
2018-03-31	CONCERT PHARMACEUTICALS, INC.F Tax Payment	Chief Development Officer	FTax Payment	−4,418 sh	$22.90	−$101K	55,582
2017-07-06	CONCERT PHARMACEUTICALS, INC.A Award	Chief Development Officer	AAward	+60K sh	—	—	60,000
2017-01-04	CONCERT PHARMACEUTICALS, INC.Employee Stock Option (right to buy)A Award	Chief Development Officer	AAward	+70K sh	—	—	70,000
2016-01-07	CONCERT PHARMACEUTICALS, INC.Employee Stock Option (right to buy)A Award	Chief Development Officer	AAward	+50K sh	—	—	50,000
2015-03-05	CONCERT PHARMACEUTICALS, INC.Employee Stock Option (right to buy)A Award	Chief Development Officer	AAward	+140K sh	—	—	140,000
2014-07-07	Alexza Pharmaceuticals Inc.Stock Option (right to buy)A Award	Director, Former EVP, R&D and CSO	AAward	+25K sh	—	—	25,000
2013-03-29	Alexza Pharmaceuticals Inc.A Award	Director, Former EVP, R&D and CSO	AAward	+43.8K sh	$4.42	+$193K	62,495
2013-03-29	Alexza Pharmaceuticals Inc.Stock Option (right to buy)A Award	Director, Former EVP, R&D and CSO	AAward	+87.5K sh	—	—	87,500
2013-03-29	Alexza Pharmaceuticals Inc.A Award	Director, Former EVP, R&D and CSO	AAward	+43.8K sh	$4.42	+$193K	62,495
2013-03-29	Alexza Pharmaceuticals Inc.Stock Option (right to buy)A Award	Director, Former EVP, R&D and CSO	AAward	+43.8K sh	—	—	43,750
2013-02-07	Alexza Pharmaceuticals Inc.A Award	Director, Former EVP, R&D and CSO	AAward	+17.8K sh	—	—	18,745
2012-12-26	Alexza Pharmaceuticals Inc.S Sale	Director, Former EVP, R&D and CSO	SSale	−4,558 sh	$4.90	−$22.3K	950

Recent filings

Accepted (ET)
Feb 204
Cassella James V0001193125-26-061399
SEC(opens sec.gov)
Feb 204
Cassella James V0000950170-25-024116
SEC(opens sec.gov)
Oct 14
Cassella James V0000950170-24-110921
SEC(opens sec.gov)
Jun 144
Cassella James V0000950170-24-073728
SEC(opens sec.gov)
Jun 304
Cassella James V0001209191-23-040289
SEC(opens sec.gov)
Mar 64
Cassella James V0001209191-23-016163
SEC(opens sec.gov)
Feb 164
Cassella James V0001209191-23-009949
SEC(opens sec.gov)
Jan 314
Cassella James V0001209191-23-005620
SEC(opens sec.gov)
Jan 94
Cassella James V0001209191-23-002551
SEC(opens sec.gov)
Jul 14/A
Cassella James V0001209191-22-040292
SEC(opens sec.gov)
Jun 234
Cassella James V0001209191-22-038901
SEC(opens sec.gov)

Companies

Address

C/O TREVI THERAPEUTICS, INC. 195 CHURCH STREET, 16TH FLOOR

NEW HAVEN, CT, 06510